Andrew Bradford
Concepts (390)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| E2F1 Transcription Factor | 12 | 2026 | 71 | 1.830 |
Why?
| | Endometrial Neoplasms | 7 | 2021 | 206 | 1.640 |
Why?
| | Follicle Stimulating Hormone | 14 | 2026 | 250 | 1.620 |
Why?
| | Luteinizing Hormone | 14 | 2026 | 191 | 1.470 |
Why?
| | Promoter Regions, Genetic | 19 | 2026 | 1255 | 1.100 |
Why?
| | Prolactin | 10 | 2022 | 92 | 1.020 |
Why?
| | Hyperlipidemias | 3 | 2022 | 121 | 0.970 |
Why?
| | Metabolic Syndrome | 5 | 2026 | 364 | 0.970 |
Why?
| | Hyperinsulinism | 3 | 2022 | 114 | 0.950 |
Why?
| | Leiomyoma | 3 | 2019 | 59 | 0.940 |
Why?
| | Obesity | 16 | 2024 | 3073 | 0.930 |
Why?
| | Uterine Neoplasms | 3 | 2019 | 96 | 0.910 |
Why?
| | Protein Kinase C-alpha | 3 | 2009 | 36 | 0.850 |
Why?
| | Gene Expression Regulation, Neoplastic | 12 | 2026 | 1496 | 0.820 |
Why?
| | E2F Transcription Factors | 6 | 2026 | 76 | 0.810 |
Why?
| | Pituitary Gland | 7 | 2021 | 153 | 0.790 |
Why?
| | Human Growth Hormone | 1 | 2022 | 46 | 0.710 |
Why?
| | Proto-Oncogene Proteins | 9 | 2015 | 628 | 0.700 |
Why?
| | Diet, High-Fat | 4 | 2026 | 262 | 0.690 |
Why?
| | Gene Expression Profiling | 6 | 2019 | 1817 | 0.680 |
Why?
| | Corpus Luteum | 3 | 2016 | 20 | 0.680 |
Why?
| | Soybean Oil | 1 | 2021 | 15 | 0.680 |
Why?
| | Protein Kinase C-delta | 5 | 2009 | 46 | 0.670 |
Why?
| | Gene Products, tax | 3 | 2025 | 15 | 0.660 |
Why?
| | Human T-lymphotropic virus 1 | 3 | 2025 | 32 | 0.660 |
Why?
| | Cell Proliferation | 11 | 2026 | 2540 | 0.640 |
Why?
| | Phospholipids | 2 | 2021 | 211 | 0.630 |
Why?
| | Leiomyosarcoma | 1 | 2019 | 29 | 0.600 |
Why?
| | Apoptosis | 12 | 2026 | 2446 | 0.550 |
Why?
| | Insulin | 5 | 2022 | 2502 | 0.500 |
Why?
| | Fibroblast Growth Factors | 4 | 2021 | 188 | 0.500 |
Why?
| | Transcriptional Activation | 5 | 2025 | 382 | 0.490 |
Why?
| | Gene Expression Regulation | 11 | 2023 | 2620 | 0.480 |
Why?
| | Signal Transduction | 12 | 2025 | 5241 | 0.470 |
Why?
| | High Fructose Corn Syrup | 1 | 2015 | 8 | 0.470 |
Why?
| | Granulosa Cells | 1 | 2015 | 33 | 0.460 |
Why?
| | Weight Gain | 2 | 2016 | 559 | 0.440 |
Why?
| | Proto-Oncogene Proteins c-ets | 8 | 2007 | 56 | 0.440 |
Why?
| | DEAD-box RNA Helicases | 2 | 2025 | 90 | 0.420 |
Why?
| | Fibroblast Growth Factor 2 | 3 | 2006 | 89 | 0.410 |
Why?
| | Cell Line, Tumor | 14 | 2026 | 3609 | 0.400 |
Why?
| | Dietary Fats | 1 | 2015 | 314 | 0.390 |
Why?
| | Adenocarcinoma | 3 | 2009 | 927 | 0.380 |
Why?
| | Transcription Factors | 8 | 2018 | 1735 | 0.380 |
Why?
| | MAP Kinase Signaling System | 3 | 2006 | 316 | 0.370 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1327 | 0.360 |
Why?
| | Retinoblastoma Protein | 4 | 2026 | 108 | 0.360 |
Why?
| | DNA-Binding Proteins | 8 | 2018 | 1493 | 0.360 |
Why?
| | MicroRNAs | 2 | 2015 | 699 | 0.350 |
Why?
| | Gonadotropins | 3 | 2023 | 39 | 0.340 |
Why?
| | Protein Kinase C | 2 | 2003 | 252 | 0.340 |
Why?
| | Cross-Over Studies | 3 | 2022 | 594 | 0.330 |
Why?
| | Aromatase Inhibitors | 3 | 2020 | 76 | 0.330 |
Why?
| | Fibroblast Growth Factor 4 | 3 | 2006 | 19 | 0.330 |
Why?
| | Homeodomain Proteins | 5 | 2012 | 524 | 0.310 |
Why?
| | Estradiol | 5 | 2023 | 538 | 0.300 |
Why?
| | Menstrual Cycle | 3 | 2026 | 140 | 0.300 |
Why?
| | Tumor Protein p73 | 2 | 2026 | 18 | 0.300 |
Why?
| | Female | 37 | 2026 | 77570 | 0.290 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2009 | 154 | 0.290 |
Why?
| | Hydrocortisone | 2 | 2022 | 305 | 0.270 |
Why?
| | Humans | 51 | 2026 | 143821 | 0.270 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2024 | 541 | 0.270 |
Why?
| | RNA, Messenger | 2 | 2015 | 2847 | 0.260 |
Why?
| | Growth Hormone | 3 | 2022 | 98 | 0.240 |
Why?
| | Ovarian Neoplasms | 1 | 2012 | 594 | 0.240 |
Why?
| | Mouse Embryonic Stem Cells | 1 | 2026 | 38 | 0.240 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2025 | 17 | 0.240 |
Why?
| | HTLV-I Infections | 1 | 2025 | 28 | 0.230 |
Why?
| | Genes, Tumor Suppressor | 4 | 2023 | 90 | 0.230 |
Why?
| | Isoenzymes | 3 | 2003 | 299 | 0.230 |
Why?
| | Neoplasms | 4 | 2026 | 2902 | 0.230 |
Why?
| | Cytokines | 4 | 2024 | 2093 | 0.220 |
Why?
| | Cell Cycle Proteins | 4 | 2023 | 636 | 0.220 |
Why?
| | Weight Loss | 2 | 2024 | 825 | 0.220 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2024 | 25 | 0.210 |
Why?
| | Tumor Cells, Cultured | 5 | 2007 | 944 | 0.210 |
Why?
| | Adipokines | 1 | 2024 | 58 | 0.210 |
Why?
| | Live Birth | 1 | 2024 | 68 | 0.200 |
Why?
| | Phosphorylation | 5 | 2024 | 1761 | 0.200 |
Why?
| | Preconception Care | 1 | 2024 | 50 | 0.200 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2016 | 115 | 0.200 |
Why?
| | Estrone | 3 | 2026 | 40 | 0.200 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2003 | 55 | 0.200 |
Why?
| | Animals | 21 | 2026 | 38140 | 0.200 |
Why?
| | Persian Gulf Syndrome | 1 | 2023 | 18 | 0.200 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2024 | 138 | 0.190 |
Why?
| | Transcription Factor DP1 | 2 | 2023 | 26 | 0.190 |
Why?
| | Irritable Bowel Syndrome | 1 | 2023 | 29 | 0.190 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2021 | 212 | 0.190 |
Why?
| | Fertility | 1 | 2024 | 167 | 0.190 |
Why?
| | Pituitary Hormones | 1 | 2022 | 16 | 0.190 |
Why?
| | Estrogens | 4 | 2026 | 377 | 0.180 |
Why?
| | Rats | 10 | 2006 | 5609 | 0.180 |
Why?
| | Transcription Factor Pit-1 | 6 | 2003 | 27 | 0.180 |
Why?
| | Thyroid Hormones | 1 | 2022 | 67 | 0.180 |
Why?
| | Thyrotropin | 1 | 2022 | 115 | 0.180 |
Why?
| | Hypothalamus | 2 | 2014 | 156 | 0.180 |
Why?
| | Transcription, Genetic | 3 | 2009 | 1504 | 0.170 |
Why?
| | Mindfulness | 1 | 2024 | 152 | 0.170 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 1997 | 267 | 0.170 |
Why?
| | Emulsions | 1 | 2021 | 57 | 0.170 |
Why?
| | Gastrointestinal Diseases | 1 | 2023 | 209 | 0.170 |
Why?
| | Tandem Mass Spectrometry | 2 | 2015 | 573 | 0.170 |
Why?
| | Heparin | 1 | 2022 | 250 | 0.160 |
Why?
| | Thinness | 1 | 2021 | 99 | 0.160 |
Why?
| | Leptin | 1 | 2022 | 244 | 0.160 |
Why?
| | Adult | 18 | 2026 | 40129 | 0.160 |
Why?
| | Gastroesophageal Reflux | 1 | 2023 | 240 | 0.160 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2021 | 158 | 0.160 |
Why?
| | Wnt Proteins | 1 | 2021 | 136 | 0.160 |
Why?
| | Adiponectin | 1 | 2022 | 247 | 0.160 |
Why?
| | Creatinine | 1 | 2022 | 492 | 0.160 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2016 | 15 | 0.160 |
Why?
| | Enzyme Activation | 3 | 2009 | 782 | 0.160 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 178 | 0.160 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 6 | 2003 | 26 | 0.160 |
Why?
| | Bcl-2-Like Protein 11 | 2 | 2016 | 37 | 0.160 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 320 | 0.150 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2019 | 18 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1065 | 0.150 |
Why?
| | Lipids | 2 | 2022 | 699 | 0.150 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2019 | 66 | 0.150 |
Why?
| | Cell Cycle | 2 | 2015 | 632 | 0.150 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 212 | 0.150 |
Why?
| | beta Catenin | 1 | 2021 | 253 | 0.150 |
Why?
| | Biomarkers | 2 | 2024 | 4248 | 0.150 |
Why?
| | Eicosapentaenoic Acid | 1 | 2019 | 36 | 0.150 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 156 | 0.140 |
Why?
| | Follicular Phase | 2 | 2015 | 38 | 0.140 |
Why?
| | Docosahexaenoic Acids | 1 | 2019 | 86 | 0.140 |
Why?
| | Tumor Suppressor Proteins | 2 | 2026 | 324 | 0.140 |
Why?
| | Gene Knockdown Techniques | 2 | 2009 | 337 | 0.140 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 197 | 0.140 |
Why?
| | Immunoenzyme Techniques | 2 | 2009 | 200 | 0.140 |
Why?
| | Pituitary Gland, Anterior | 1 | 1997 | 38 | 0.140 |
Why?
| | Etoposide | 2 | 2009 | 166 | 0.130 |
Why?
| | Young Adult | 11 | 2026 | 13914 | 0.130 |
Why?
| | Genes, p16 | 1 | 2016 | 13 | 0.130 |
Why?
| | Pregnancy | 4 | 2024 | 7154 | 0.120 |
Why?
| | Aromatase | 2 | 2014 | 32 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 1996 | 64 | 0.120 |
Why?
| | Fibroblasts | 3 | 2018 | 1035 | 0.120 |
Why?
| | Mice, Nude | 2 | 2025 | 692 | 0.120 |
Why?
| | Genes, ras | 2 | 1997 | 96 | 0.120 |
Why?
| | Blotting, Western | 2 | 2009 | 1207 | 0.120 |
Why?
| | Stress, Psychological | 1 | 2024 | 1147 | 0.120 |
Why?
| | Ovulation | 1 | 2015 | 41 | 0.110 |
Why?
| | Dietary Supplements | 2 | 2019 | 576 | 0.110 |
Why?
| | Cumulus Cells | 1 | 2015 | 6 | 0.110 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 104 | 0.110 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 466 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1502 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 878 | 0.110 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2015 | 188 | 0.110 |
Why?
| | Tumor Suppressor Protein p14ARF | 1 | 2014 | 7 | 0.110 |
Why?
| | Transcription Factors, TFII | 2 | 2024 | 44 | 0.110 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 384 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1984 | 0.110 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 110 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 142 | 0.110 |
Why?
| | Hormone Antagonists | 1 | 2014 | 34 | 0.100 |
Why?
| | Luteal Phase | 1 | 2014 | 46 | 0.100 |
Why?
| | Hypogonadism | 3 | 2024 | 93 | 0.100 |
Why?
| | Transfection | 3 | 2009 | 952 | 0.100 |
Why?
| | Repressor Proteins | 1 | 1997 | 432 | 0.100 |
Why?
| | Neoplasms, Experimental | 1 | 2014 | 172 | 0.100 |
Why?
| | RNA Interference | 2 | 2018 | 482 | 0.100 |
Why?
| | Circadian Rhythm | 1 | 2017 | 516 | 0.100 |
Why?
| | Culture Media, Serum-Free | 2 | 2003 | 43 | 0.090 |
Why?
| | Postmenopause | 1 | 2015 | 390 | 0.090 |
Why?
| | Base Sequence | 3 | 2012 | 2186 | 0.090 |
Why?
| | DNA Fingerprinting | 1 | 2012 | 32 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2018 | 645 | 0.090 |
Why?
| | Exercise | 1 | 2024 | 2196 | 0.090 |
Why?
| | Cell Line | 5 | 2018 | 2906 | 0.090 |
Why?
| | DNA, Complementary | 2 | 2012 | 278 | 0.090 |
Why?
| | Mice | 6 | 2026 | 18421 | 0.090 |
Why?
| | Breast Neoplasms | 3 | 2012 | 2497 | 0.090 |
Why?
| | Body Mass Index | 4 | 2026 | 2439 | 0.080 |
Why?
| | Pulsatile Flow | 1 | 2011 | 55 | 0.080 |
Why?
| | NF-kappa B | 2 | 2025 | 668 | 0.080 |
Why?
| | Cell Survival | 2 | 2021 | 1110 | 0.080 |
Why?
| | Protein Isoforms | 2 | 2003 | 403 | 0.080 |
Why?
| | Testosterone | 1 | 2015 | 426 | 0.080 |
Why?
| | Veterans | 1 | 2023 | 1586 | 0.080 |
Why?
| | Pituitary Neoplasms | 2 | 2003 | 191 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 991 | 0.080 |
Why?
| | Adiposity | 1 | 2015 | 537 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 95 | 0.080 |
Why?
| | Mutation | 1 | 2021 | 4106 | 0.080 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 69 | 0.080 |
Why?
| | Infertility, Female | 2 | 2024 | 112 | 0.080 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2009 | 73 | 0.080 |
Why?
| | Luciferases | 1 | 2009 | 153 | 0.080 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2009 | 81 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 481 | 0.080 |
Why?
| | Progesterone | 3 | 2016 | 255 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 765 | 0.070 |
Why?
| | Cyclin D1 | 1 | 2009 | 68 | 0.070 |
Why?
| | Mutant Proteins | 1 | 2009 | 105 | 0.070 |
Why?
| | NIH 3T3 Cells | 1 | 2009 | 151 | 0.070 |
Why?
| | Models, Biological | 2 | 2016 | 1833 | 0.070 |
Why?
| | Inflammation | 2 | 2024 | 2893 | 0.070 |
Why?
| | Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2015 | 1182 | 0.070 |
Why?
| | PTEN Phosphohydrolase | 1 | 2009 | 166 | 0.070 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2012 | 559 | 0.070 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 90 | 0.070 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 410 | 0.070 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 272 | 0.070 |
Why?
| | Myometrium | 1 | 2008 | 39 | 0.070 |
Why?
| | Rabbits | 1 | 2009 | 656 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 165 | 0.070 |
Why?
| | Cell Adhesion | 1 | 2009 | 457 | 0.070 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 515 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1688 | 0.070 |
Why?
| | DNA Primers | 1 | 2008 | 516 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 442 | 0.060 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2007 | 124 | 0.060 |
Why?
| | Subcellular Fractions | 1 | 2006 | 75 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-raf | 2 | 1997 | 45 | 0.060 |
Why?
| | HeLa Cells | 2 | 2000 | 653 | 0.060 |
Why?
| | Mammary Glands, Human | 1 | 2007 | 68 | 0.060 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2016 | 89 | 0.060 |
Why?
| | Immunoprecipitation | 1 | 2006 | 152 | 0.060 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2006 | 90 | 0.060 |
Why?
| | Ultraviolet Rays | 1 | 2009 | 387 | 0.060 |
Why?
| | Pregnanediol | 1 | 2026 | 22 | 0.060 |
Why?
| | Growth Hormone-Releasing Hormone | 1 | 2006 | 25 | 0.060 |
Why?
| | raf Kinases | 1 | 2006 | 12 | 0.060 |
Why?
| | DNA Damage | 1 | 2009 | 432 | 0.060 |
Why?
| | Autocrine Communication | 1 | 2006 | 40 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1997 | 167 | 0.060 |
Why?
| | Receptors, Growth Factor | 1 | 2006 | 56 | 0.060 |
Why?
| | Prostate | 1 | 2007 | 157 | 0.060 |
Why?
| | Caspases | 1 | 2006 | 234 | 0.060 |
Why?
| | Paracrine Communication | 1 | 2006 | 68 | 0.060 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2006 | 179 | 0.060 |
Why?
| | Middle Aged | 3 | 2024 | 35630 | 0.060 |
Why?
| | Reproduction | 1 | 2007 | 207 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2009 | 1000 | 0.060 |
Why?
| | ras Proteins | 1 | 2006 | 155 | 0.060 |
Why?
| | Hypothalamo-Hypophyseal System | 2 | 2017 | 201 | 0.060 |
Why?
| | Protein Binding | 2 | 2024 | 2261 | 0.050 |
Why?
| | Prospective Studies | 4 | 2023 | 7900 | 0.050 |
Why?
| | Adolescent | 7 | 2021 | 22233 | 0.050 |
Why?
| | Oncogene Protein p65(gag-jun) | 1 | 2004 | 2 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2006 | 298 | 0.050 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2024 | 7 | 0.050 |
Why?
| | Ideal Body Weight | 1 | 2024 | 4 | 0.050 |
Why?
| | Cell Movement | 1 | 2009 | 973 | 0.050 |
Why?
| | Cyclin D2 | 1 | 2024 | 5 | 0.050 |
Why?
| | Ovulation Induction | 2 | 2015 | 56 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2004 | 55 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2007 | 619 | 0.050 |
Why?
| | Jurkat Cells | 1 | 2024 | 118 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2024 | 46 | 0.050 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2024 | 79 | 0.050 |
Why?
| | Diet, Fat-Restricted | 1 | 2024 | 79 | 0.050 |
Why?
| | Pregnancy Rate | 1 | 2024 | 70 | 0.050 |
Why?
| | Phospholipid Ethers | 1 | 2003 | 4 | 0.050 |
Why?
| | Thiocarbamates | 1 | 2003 | 6 | 0.050 |
Why?
| | Gene Expression | 2 | 2021 | 1512 | 0.050 |
Why?
| | Thiones | 1 | 2003 | 13 | 0.050 |
Why?
| | Norbornanes | 1 | 2003 | 14 | 0.050 |
Why?
| | Chromones | 1 | 2003 | 43 | 0.050 |
Why?
| | E2F3 Transcription Factor | 1 | 2023 | 8 | 0.050 |
Why?
| | Bridged-Ring Compounds | 1 | 2003 | 31 | 0.050 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 12 | 0.050 |
Why?
| | Culturally Competent Care | 1 | 2024 | 69 | 0.050 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1733 | 0.050 |
Why?
| | Gulf War | 1 | 2023 | 15 | 0.050 |
Why?
| | Androstadienes | 1 | 2003 | 79 | 0.050 |
Why?
| | Abortion, Spontaneous | 1 | 2024 | 114 | 0.050 |
Why?
| | Cell Death | 1 | 2024 | 387 | 0.050 |
Why?
| | Thyroid Neoplasms | 1 | 2007 | 346 | 0.050 |
Why?
| | Protein Domains | 1 | 2024 | 313 | 0.050 |
Why?
| | Morpholines | 1 | 2003 | 128 | 0.050 |
Why?
| | Molecular Sequence Data | 4 | 2012 | 2914 | 0.050 |
Why?
| | Cluster Analysis | 2 | 2015 | 530 | 0.050 |
Why?
| | Acetophenones | 1 | 2001 | 13 | 0.040 |
Why?
| | Models, Molecular | 1 | 2007 | 1600 | 0.040 |
Why?
| | Benzopyrans | 1 | 2001 | 27 | 0.040 |
Why?
| | Carbazoles | 1 | 2001 | 56 | 0.040 |
Why?
| | Naphthalenes | 1 | 2001 | 57 | 0.040 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 43 | 0.040 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 31 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2024 | 511 | 0.040 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 29 | 0.040 |
Why?
| | Focus Groups | 1 | 2024 | 573 | 0.040 |
Why?
| | Immunoblotting | 1 | 2001 | 307 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 79 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2004 | 379 | 0.040 |
Why?
| | Adenoviridae | 1 | 2001 | 203 | 0.040 |
Why?
| | Self Efficacy | 1 | 2024 | 411 | 0.040 |
Why?
| | Genetic Fitness | 1 | 2021 | 59 | 0.040 |
Why?
| | Glucose Clamp Technique | 1 | 2021 | 200 | 0.040 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 140 | 0.040 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 119 | 0.040 |
Why?
| | Imidazoles | 1 | 2021 | 255 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 351 | 0.040 |
Why?
| | DNA | 2 | 1997 | 1427 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 684 | 0.040 |
Why?
| | Aged | 1 | 2019 | 25615 | 0.040 |
Why?
| | Histones | 1 | 2024 | 655 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2007 | 927 | 0.040 |
Why?
| | ADP-Ribosylation Factors | 1 | 2018 | 18 | 0.040 |
Why?
| | Self Report | 1 | 2023 | 865 | 0.040 |
Why?
| | Progestins | 1 | 2019 | 87 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2024 | 682 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2006 | 2045 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 440 | 0.030 |
Why?
| | Dimerization | 1 | 2018 | 194 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2001 | 832 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2021 | 537 | 0.030 |
Why?
| | Recurrence | 1 | 2021 | 1122 | 0.030 |
Why?
| | Indoles | 1 | 2001 | 479 | 0.030 |
Why?
| | Proto-Oncogene Protein c-ets-2 | 1 | 1997 | 4 | 0.030 |
Why?
| | Ectopic Gene Expression | 1 | 2016 | 5 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 639 | 0.030 |
Why?
| | ets-Domain Protein Elk-1 | 1 | 1996 | 11 | 0.030 |
Why?
| | Catalysis | 1 | 1997 | 326 | 0.030 |
Why?
| | Pyridines | 1 | 2021 | 612 | 0.030 |
Why?
| | Pituitary-Adrenal System | 1 | 2017 | 168 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 1996 | 136 | 0.030 |
Why?
| | Hormones | 1 | 2016 | 136 | 0.030 |
Why?
| | Administration, Cutaneous | 1 | 2015 | 128 | 0.030 |
Why?
| | Oocyte Retrieval | 1 | 2015 | 12 | 0.030 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 65 | 0.030 |
Why?
| | Limit of Detection | 1 | 2015 | 95 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2016 | 196 | 0.030 |
Why?
| | Genes, Transgenic, Suicide | 1 | 2014 | 7 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1997 | 435 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 277 | 0.030 |
Why?
| | Trans-Activators | 1 | 1997 | 398 | 0.030 |
Why?
| | Binding Sites | 1 | 1997 | 1312 | 0.030 |
Why?
| | Cellular Microenvironment | 1 | 2015 | 93 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1997 | 683 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 345 | 0.030 |
Why?
| | Chromosome Mapping | 1 | 1995 | 511 | 0.030 |
Why?
| | Ovary | 1 | 2015 | 227 | 0.030 |
Why?
| | Anions | 1 | 2013 | 31 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2015 | 396 | 0.020 |
Why?
| | Molecular Conformation | 1 | 2013 | 148 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 454 | 0.020 |
Why?
| | Fatty Acids | 1 | 2015 | 450 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2098 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2012 | 157 | 0.020 |
Why?
| | Genetic Therapy | 1 | 2014 | 322 | 0.020 |
Why?
| | Heterografts | 1 | 2012 | 145 | 0.020 |
Why?
| | Gene Library | 1 | 2012 | 126 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2015 | 1223 | 0.020 |
Why?
| | Protein Kinases | 1 | 1992 | 315 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 904 | 0.020 |
Why?
| | Nitriles | 1 | 2011 | 204 | 0.020 |
Why?
| | Triazoles | 1 | 2011 | 181 | 0.020 |
Why?
| | Male | 4 | 2017 | 71569 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 779 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11459 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 828 | 0.020 |
Why?
| | Receptors, Pituitary Hormone-Regulating Hormone | 1 | 2006 | 8 | 0.020 |
Why?
| | Receptors, Neuropeptide | 1 | 2006 | 11 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5761 | 0.010 |
Why?
| | Transcriptome | 1 | 2012 | 1047 | 0.010 |
Why?
| | Prognosis | 1 | 2012 | 4210 | 0.010 |
Why?
| | Liver | 1 | 1992 | 1846 | 0.010 |
Why?
| | Suppression, Genetic | 1 | 2003 | 24 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 100 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2004 | 342 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4553 | 0.010 |
Why?
| | Amino Acid Sequence | 2 | 1997 | 2148 | 0.010 |
Why?
| | Phosphothreonine | 1 | 1997 | 6 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1997 | 362 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1997 | 392 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1997 | 567 | 0.010 |
Why?
| | Drosophila Proteins | 1 | 1997 | 206 | 0.010 |
Why?
| | Nerve Tissue Proteins | 1 | 1997 | 600 | 0.010 |
Why?
| | Biological Evolution | 1 | 1997 | 489 | 0.010 |
Why?
| | Chromatography, Ion Exchange | 1 | 1992 | 56 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 1992 | 129 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1992 | 320 | 0.010 |
Why?
| | Molecular Weight | 1 | 1992 | 325 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 330 | 0.010 |
Why?
| | Cytosol | 1 | 1992 | 225 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1992 | 379 | 0.010 |
Why?
| | Peptides | 1 | 1997 | 986 | 0.010 |
Why?
| | Oligopeptides | 1 | 1992 | 267 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1997 | 4172 | 0.000 |
Why?
| | Kinetics | 1 | 1992 | 1622 | 0.000 |
Why?
|
|
Bradford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|